The U.S. House of Representatives recently passed the BIOSECURE Act, which prohibits U.S. biopharma companies from collaborating with Chinese contractors. The Act, propelled by concerns about national security, including data leaks and intellectual property theft from U.S. companies, now moves to the Senate, where it is expected to pass.
The impact is a ripple effect across the biopharmaceutical supply chain. U.S. companies will be forced to find alternative suppliers by January 2032. As a…
Read More…
Long version of The BIOSECURE Act: The West’s Wake-Up Call to China’s Biotech Dominance
